Radiopharm Theranostics (NASDAQ:RADX) Given "Sell (E+)" Rating at Weiss Ratings

Key Points

• Weiss Ratings reaffirmed a "sell (e+)" rating for Radiopharm Theranostics (NASDAQ:RADX), indicating a negative outlook from the analysts.
• Brookline Capital Management initiated coverage with a "buy" rating and set a price target of $18.00, contrasting with the consensus average price target of $15.00.
• PNC Financial Services Group acquired a new stake in Radiopharm Theranostics, purchasing 8,000 shares valued at approximately $37,000.

Radiopharm Theranostics (NASDAQ:RADX - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Separately, Brookline Capital Management began coverage on Radiopharm Theranostics in a research note on Monday, July 21st. They issued a "buy" rating and a $18.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Radiopharm Theranostics has an average rating of "Buy" and a consensus price target of $15.00.

Radiopharm Theranostics Trading Up 7.1%

Shares of RADX stock opened at $7.54 on Wednesday. The firm has a 50 day moving average of $5.78. Radiopharm Theranostics has a one year low of $3.50 and a one year high of $50.82.

Hedge Funds Weigh In On Radiopharm Theranostics

A hedge fund recently bought a new stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. bought a new position in shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 8,000 shares of the company's stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned 0.10% of Radiopharm Theranostics as of its most recent SEC filing.

About Radiopharm Theranostics

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.